BioSpace News Archive

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:50 a.m. ET. The live webcast will be accessible under Events and Presentations in the Investors section of the company’s website. This archived webcast will

The South Korean biotech company Y-Biologics and the China -based biopharmaceutical company 3D Medicines have entered into a License Agreement granting exclusive rights to develop, manufacture, and commercialize YBL-013, a T cell bi-specific engager based on ALiCE platform technology, in the Territory of Great

Volta Medical, a pioneering French-based HealthTech startup, working on novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised 28 million USD.

Brightseed Announces Preclinical Data For Phytonutrients Targeting Liver and Metabolic Health AI-Powered Discovery Shows Novel Biological Mechanism, Moves Into Clinical Trials in 2021

Limitless Venture Group, Inc. is excited to announce that it has contracted EDM Media LLC, a leading Public Relations and Media firm, to broaden the Company’s presence and visibility on social and digital media and help communicate LVGI’s message and vision to a wider audience as the Company expands its operations and achievements in 2021.

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of the settlement of patent litigation with Osmotica Pharmaceutical US LLC, a subsidiary of Osmotica Pharmaceuticals plc and completes the acquisition of the global rights to OSMOLEX ER®. As previously disclosed, the amended Royalty-

The Seasoned Technology Executive Brings the Board Over 40 Years of Experience Driving Market Share Gains and Mission Critical Business Transformations

FDA Extends Shelf Life of Octapharma’s cutaquig ® 16.5% for Adult PI Patients As concerns about the supply of immunoglobulin rise, FDA extends expiration date for certain existing lots already in distribution and all new lots of Octapharma’s SCIg

Phoenix PharmaLabs, a privately-held pre-clinical drug discovery company dedicated to the development of potent, non-addictive treatments for pain and addiction, today announced it has completed a license agreement with the University of Bath in England for exclusive rights to a portfolio of 25 NOP (Nociceptin) compounds. The specific terms of the license agreement were not disclosed. One of the compounds, formerly kn

ResMed Announces Participation in the 39 th Annual J.P. Morgan Healthcare Conference